Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Selonsertib in Hepatic Impairment
NCT02509624Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selonsertib in diabetic kidney disease (DKD) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity, Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Started Aug 2015; status: completed.
02
Drugs
selonsertib
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT02509624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02509624.